Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII

Ramanathan, Mathura P.; Kutzler, Michele A.; Kuo, Yuan-Chia; Yan, Jian; Liu, Harrison; Shah, Vidhi V.; Bawa, Amrit; Selling, Bernard; Sardesai, Niranjan Y.; Kim, J. Joseph; Weiner, David B.

doi:10.1016/j.vaccine.2009.01.137

Cited by 41 publications

(27 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In HIV infection, the injection of IL-15 enhanced the survival and effector function of HIV-specific CD8C T-cells and, when exogenously increased by administration of a IL-15 coding plasmid, was shown to be a potent adjuvant by stimulating CD8 T-cell response and longevity as well as increasing IFNg production. [151][152] Finally, IL-21 is a cytokine involved in CD8 T-cell proliferation and activation and controls the differentiation of na€ ıve CD4 T-cell in Th17 cells; this molecule is defective in SIV-infected rhesus macaques and this deficit is associated with Th17 cell depletion. 153 In untreated rhesus macaques with SIV infection the administration of IL-21 led to an increase in the cytotoxic potential of T cells without enhancing cellular activation, 154 and in HAART-receiving animals drove a reduction of immune activation and a restoration of intestinal Th17 and Th22.…”

Section: New Treatment Strategies and Immunotherapy In Aging Hiv Patimentioning

confidence: 99%

Immunosenescence and hurdles in the clinical management of older HIV-patients

2017

View full text Add to dashboard Cite

People living with HIV (PLWH) who are treated with effective highly active antiretroviral therapy (HAART) have a similar life expectancy to the general population. Moreover, an increasing proportion of new HIV diagnoses are made in people older than 50 y. The number of older HIVinfected patients is thus constantly growing and it is expected that by 2030 around 70% of PLWH will be more than 50 y old. On the other hand, HIV infection itself is responsible for accelerated immunosenescence, a progressive decline of immune system function in both the adaptive and the innate arm, which impairs the ability of an individual to respond to infections and to give rise to long-term immunity; furthermore, older patients tend to have a worse immunological response to HAART.In this review we focus on the pathogenesis of HIV-induced immunosenescence and on the clinical management of older HIV-infected patients.

show abstract

Section: New Treatment Strategies and Immunotherapy In Aging Hiv Patimentioning

confidence: 99%

Immunosenescence and hurdles in the clinical management of older HIV-patients

2017

View full text Add to dashboard Cite

show abstract

“…Combining IL-15 with CpG generated synergistic effect on the immunogenicity of a SIV mucosal vaccine [344]. Similarly, plasmids encoding IL-15 could also be effective for a variety of vaccines tested in mice, such as a tumor antigen-derived peptide vaccine [345], HIV-1 DermaVir vaccine formulated with HIV-1 Gag plasmid (more potent than IL-7) [346] and flaviviruse DNA vaccine [347].…”

Section: Interleukinsmentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

“…However, to date no DNA vaccines have been licensed for use in humans. DNA vaccines expressing the prM and Env proteins from WNV [63-65] or the domain III (DIII) region of the Env protein [66] have been developed and tested in both mice and horses. Other approaches to DNA vaccines have included constructs encoding for single-round infectious particles (SRIP) [67,68] or a full-length cDNA copy of the attenuated Kunjin strain of WNV [69].…”

Section: Vaccines In Pre-clinical Developmentmentioning

confidence: 99%

Current trends in West Nile virus vaccine development

Amanna

Slifka

2014

Expert Review of Vaccines

View full text Add to dashboard Cite

West Nile virus (WNV) is a mosquito-borne flavivirus that has become endemic in the United States. From 1999-2012, there have been 37,088 reported cases of WNV and 1,549 deaths, resulting in a 4.2% case-fatality rate. Despite development of effective WNV vaccines for horses, there is no vaccine to prevent human WNV infection. Several vaccines have been tested in preclinical studies and to date there have been 8 clinical trials, with promising results in terms of safety and induction of antiviral immunity. Although mass vaccination is unlikely to be cost-effective, implementation of a targeted vaccine program may be feasible if a safe and effective vaccine can be brought to market. Further evaluation of new and advanced vaccine candidates is strongly encouraged.

show abstract

Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII

Cited by 41 publications

References 49 publications

Immunosenescence and hurdles in the clinical management of older HIV-patients

Immunosenescence and hurdles in the clinical management of older HIV-patients

Selection of Adjuvants for Enhanced Vaccine Potency

Current trends in West Nile virus vaccine development

Contact Info

Product

Resources

About